- Home
- NIM vs UNCY Comparison
NIM vs UNCY Comparison
Compare NIM & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NIM | UNCY |
|---|---|---|
| Founded | 1992 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7M | 126.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NIM | UNCY |
|---|---|---|
| Price | $9.29 | $5.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $44.50 |
| AVG Volume (30 Days) | 35.4K | ★ 358.3K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.28 | $3.71 |
| 52 Week High | $9.74 | $11.00 |
Technical Indicators
Market Signals| Indicator | NIM | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 48.15 | 46.02 |
| Support Level | $9.20 | $5.35 |
| Resistance Level | $9.37 | $6.95 |
| Average True Range (ATR) | 0.08 | 0.38 |
| MACD | -0.00 | -0.15 |
| Stochastic Oscillator | 45.00 | 12.85 |
Price Performance
Historical ComparisonAbout NIM Nuveen Select Maturities Municipal Fund
Nuveen Select Maturities Municipal Fund is a diversified closed-end management investment company. Its primary investment objective is to provide current income exempt from regular federal income tax, consistent with the preservation of capital. Its secondary investment objective is to enhance portfolio value relative to the municipal bond market through investments in tax-exempt municipal obligations that are underrated or undervalued, or that represent municipal market sectors that are undervalued.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.